Prognosis factors for recurrence in patients with locally advanced rectal cancer preoperatively treated with chemoradiotherapy and adjuvant chemotherapy

Diseases of the Colon and Rectum

Volumn 56, Issue 4, 2013, Pages 416-421

  Arredondo, Jorge ^a   Baixauli, Jorge ^a   Beorlegui, Carmen ^b   Arbea, Leire ^a   Rodríguez, Javier ^a   Sola, Jesús Javier ^a   Chopitea, Ana ^a   Hernández Lizoáin, José Luís ^a  

^a UNIVERSITY CLINIC OF NAVARRA   (Spain)

^b UNIVERSITY OF NAVARRA   (Spain)

Author keywords

Locally advanced rectal cancer; Neoadjuvant combined therapy

Indexed keywords

CAPECITABINE; FLUOROPYRIMIDINE; FLUOROURACIL; OXALIPLATIN;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER REGRESSION; CHEMORADIOTHERAPY; EXTERNAL BEAM RADIOTHERAPY; FEMALE; FOLLOW UP; HUMAN; LIVER METASTASIS; MAJOR CLINICAL STUDY; MALE; PREOPERATIVE CARE; RECTUM CARCINOMA; RECURRENCE RISK;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CARCINOMA; CHEMORADIOTHERAPY; CHEMOTHERAPY, ADJUVANT; COHORT STUDIES; DEOXYCYTIDINE; FEMALE; FLUOROURACIL; HUMANS; LIVER NEOPLASMS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOADJUVANT THERAPY; NEOPLASM GRADING; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; ORGANOPLATINUM COMPOUNDS; PROGNOSIS; RECTAL NEOPLASMS; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 84876268194     PISSN: 00123706     EISSN: 15300358     Source Type: Journal    
DOI: 10.1097/DCR.0b013e318274d9c6     Document Type: Article

References (39)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010;60:277-300.
2. van Gijn W, Marijnen CA, Nagtegaal ID, et al; Dutch Colorectal Cancer Group. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer: 12-year followup of the multicentre, randomised controlled TME trial. Lancet Oncol. 2011;12:575-582.
3. Medical Research Council Rectal Cancer Working Party. Randomised trial of surgery alone versus surgery followed by radiotherapy for mobile cancer of the rectum. Lancet. 1996;348:1610-1614.
4. MacFarlane JK, Ryall RD, Heald RJ. Mesorectal excision for rectal cancer. Lancet. 1993;341:457-460.
5. Sauer R, Becker H, Hohenberger W, et al; German Rectal Cancer Study Group. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med. 2004;351:1731-1740.
6. Bosset JF, Collette L, Calais G, et al; EORTC Radiotherapy Group Trial 22921. Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med. 2006;355:1114-1123.
7. Ruo L, Tickoo S, Klimstra DS, et al. Long-term prognostic significance of extent of rectal cancer response to preoperative radiation and chemotherapy. Ann Surg. 2002;236:75-81.
8. Pucciarelli S, Friso ML, Toppan P, et al. Preoperative combined radiotherapy and chemotherapy for middle and lower rectal cancer: preliminary results. Ann Surg Oncol. 2000;7:38-44.
9. Valentini V, Coco C, Cellini N, et al. Preoperative chemoradiation for extraperitoneal T3 rectal cancer: acute toxicity, tumor response, and sphincter preservation. Int J Radiat Oncol Biol Phys. 1998;40:1067-1075.
10. Guillem JG, Chessin DB, Cohen AM, et al. Long-term oncologic outcome following preoperative combined modality therapy and total mesorectal excision of locally advanced rectal cancer. Ann Surg. 2005;241:829-836.
11. Feliu J, Calvilio J, Escribano A, et al. Neoadjuvant therapy of rectal carcinoma with UFT-leucovorin plus radiotherapy. Ann Oncol. 2002;13:730-736.
12. Grann A, Feng C, Wong D, et al. Preoperative combined modality therapy for clinically resectable uT3 rectal adenocarcinoma. Int J Radiat Oncol Biol Phys. 2001;49:987-995.
13. Scott NA, Susnerwala S, Gollins S, Myint AS, Levine E. Preoperative neo-adjuvant therapy for curable rectal cancer-reaching a consensus 2008. Colorectal Dis. 2009;11:245-248.
14. Jin J, Meng H, Zhou G, et al. Preoperative radiotherapy combined with capecitabine chemotherapy in Chinese patients with locally advanced rectal cancer. J Gastrointest Surg. 2011;15:1858-1865.
15. Bujko K, Glynne-Jones R, Bujko M. Does adjuvant fluoropyrimidine- based chemotherapy provide a benefit for patients with resected rectal cancer who have already received neoadjuvant radiochemotherapy? A systematic review of randomised trials. Ann Oncol. 2010;21:1743-1750.
16. Kiran RP, Kirat HT, Burgess AN, Nisar PJ, Kalady MF, Lavery IC. Is adjuvant chemotherapy really needed after curative surgery for rectal cancer patients who are node-negative after neoadjuvant chemoradiotherapy? Ann Surg Oncol. 2012;19:1206-1212.
17. Dalton L, Page DL. Grading breast cancer on microarray samples: comparison with Nottingham grade, and use of boosting classification. Histopathology. 2012;61:497-508.
18. Aristu JJ, Arbea L, Rodriguez J, et al. Phase I-II trial of concurrent capecitabine and oxaliplatin with preoperative intensity-modulated radiotherapy in patients with locally advanced rectal cancer. Int J Radiat Oncol Biol Phys. 2008;71:748-755.
19. Arbea L, Martínez-Monge R, Díaz-González JA, et al. Fourweek neoadjuvant intensity-modulated radiation therapy with concurrent capecitabine and oxaliplatin in locally advanced rectal cancer patients: a validation phase II trial. Int J Radiat Oncol Biol Phys. 2012;83:587-593.
20. NCCN Clinical Practice Guidelines in Oncology. Available at: http://www.nccn.org. Accessed April 17, 2012.
21. Maas M, Nelemans PJ, Valentini V, et al. Long-term outcome in patients with a pathological complete response after chemoradiation for rectal cancer: a pooled analysis of individual patient data. Lancet Oncol. 2010;11:835-844.
22. Martin ST, Heneghan HM, Winter DC. Systematic review and meta-analysis of outcomes following pathological complete response to neoadjuvant chemoradiotherapy for rectal cancer. Br J Surg. 2012;99:918-928.
23. García-Aguilar J, Hernandez de Anda E, Sirivongs P, Lee SH, Madoff RD, Rothenberger DA. A pathologic complete response to preoperative chemoradiation is associated with lower local recurrence and improved survival in rectal cancer patients treated by mesorectal excision. Dis Colon Rectum. 2003;46:298-304.
24. Vecchio FM, Valentini V, Minsky BD, et al. The relationship of pathologic tumor regression grade (TRG) and outcomes after preoperative therapy in rectal cancer. Int J Radiat Oncol Biol Phys. 2005;62:752-760.
25. Rödel C, Liersch T, Becker H, et al; German Rectal Cancer Study Group. Preoperative chemoradiotherapy and postoperative chemotherapy with fluorouracil and oxaliplatin versus fluorouracil alone in locally advanced rectal cancer: initial results of the German CAO /ARO/AIO-04 randomised phase 3 trial. Lancet Oncol. 2012;13:679-687.
26. Burke SJ, Percarpio BA, Knight DC, Kwasnik EM. Combined preoperative radiation and mitomycin/5-fluorouracil treatment for locally advanced rectal adenocarcinoma. J Am Coll Surg. 1998;187:164-170.
27. Bujko K, Nowacki MP, Nasierowska-Guttmejer A, Michalski W, Bebenek M, Kryj M. Long-term results of a randomized trial comparing preoperative short-course radiotherapy with preoperative conventionally fractionated chemoradiation for rectal cancer. Br J Surg. 2006;93:1215-1223.
28. Kobayashi H, Mochizuki H, Sugihara K, et al. Characteristics of recurrence and surveillance tools after curative resection for colorectal cancer: a multicenter study. Surgery. 2007;141:67-75.
29. Mitry E, Guiu B, Cosconea S, Jooste V, Faivre J, Bouvier AM. Epidemiology, management and prognosis of colorectal cancer with lung metastases: a 30-year population-based study. Gut. 2010;59:1383-1388.
30. Ding P, Liska D, Tang P, et al. Pulmonary recurrence predominates after combined modality therapy for rectal cancer: an original retrospective study. Ann Surg. 2012;256:111-116.
31. Tepper JE, O'Connell M, Hollis D, Niedzwiecki D, Cooke E, Mayer RJ; Intergroup Study 0114. Analysis of surgical salvage after failure of primary therapy in rectal cancer: results from Intergroup Study 0114. J Clin Oncol. 2003;21:3623-3628.
32. Watanabe K, Saito N, Sugito M, Ito M, Kobayashi A, Nishizawa Y. Predictive factors for pulmonary metastases after curative resection of rectal cancer without preoperative chemoradiotherapy. Dis Colon Rectum. 2011;54:989-998.
33. Fidler IJ. The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited. Nat Rev Cancer. 2003;3:453-458.
34. Assersohn L, Norman A, Cunningham D, Benepal T, Ross PJ, Oates J. Influence of metastatic site as an additional predictor for response and outcome in advanced colorectal carcinoma. Br J Cancer. 1999;79:1800-1805.
35. Yamada H, Ichikawa W, Uetake H, et al. Thymidylate synthase gene expression in primary colorectal cancer and metastatic sites. Clin Colorectal Cancer. 2001;1:169-174.
36. Kirke R, Rajesh A, Verma R, Bankart MJ. Rectal cancer: incidence of pulmonary metastases on thoracic CT and correlation with T staging. J Comput Assist Tomogr. 2007;31:569-571.
37. Desch CE, Benson AB 3rd, Somerfield MR, et al; American Society of Clinical Oncology. Colorectal cancer surveillance: 2005 update of an American Society of Clinical Oncology practice guideline. J Clin Oncol. 2005;23:8512-8519.
38. Lee WS, Yun SH, Chun HK, et al. Pulmonary resection for metastases from colorectal cancer: prognostic factors and survival. Int J Colorectal Dis. 2007;22:699-704.
39. Tjandra JJ, Chan MK. Follow-up after curative resection of colorectal cancer: a meta-analysis. Dis Colon Rectum. 2007;50:1783-1799.